Abstract Number: PB2155
Meeting: ISTH 2020 Congress
Theme: Venous Thromboembolism and Cardioembolism » Cancer Associated Thrombosis
Background: The imbalance between vWF and ADAMTS13 activity are associated with thrombotic complications in cancer patients, while low ADAMTS13 activity demonstrates prognostic potential.
Aims: To determine the dynamics of vWF and ADAMTS13 activity changes depending on the stage of ovarian cancer spread.
Methods: 127 patients with ovarian cancer of various stages in the perioperative period were examined: 42 patients with stage I ovarian cancer, 41 patients – stage II ovarian cancer and 44 patients with advanced ovarian cancer.
Results: In patients with I stage ovarian cancer, the median activity of ADAMTS13 and vWF was within normal ranges, while the ADAMTS13/vWF ratio was within 75 percentile. Patients with II stage of ovarian cancer had ADAMTS13 and vWF activity also within normal ranges, but their ratio was within 45 percentile. In patients with advanced ovarian cancer, the median of vWF activity was close to the upper limit of normal and ADAMTS13 to the lower limit of normal, their ratio was within 30 percentile, but the level of ADMATS13 inhibitor was also within the upper limit of normal.
Conclusions: We have shown a clear trend towards increasing vWF activity and decreasing ADAMTS13 activity depending on the degree of ovarian cancer spread. In addition, the ADAMTS13/vWF ratio tended to decrease down to 30 percentiles. An increase in the level of ADAMTS13 inhibitor was also demonstrated. In malignant neoplasms, a change in the proportional ratio of ADAMTS13/vWF may be the result of excess metalloproteinase consumption due to excess ULvWF expression by activated endothelium cancer cells.
Normal range | Ovarian cancer I stage | Ovarian cancer II stage | Advanced ovarian cancer | |
vWF activity | 70-130% | 96±14,8 | 112±19,7 | 128±22,1 |
ADAMTS13 activity | 40-130% | 72±9,2 | 51±13,7 | 39±17,8 |
ADAMTS13 inhibitor level | <12 IU/ml | 2,1±0,4 | 6,5±1,2 | 11,5±3,7 |
ADAMTS13/vWF ratio | 75% | 45,5% | 30,5% |
[ADAMTS13 and vWF activity in patients with ovarian cancer]
To cite this abstract in AMA style:
Vorobev A, Bitsadze V, Khizroeva J, Makatsariya A, Solopova A, Meng M. Dynamics of ADAMTS13 and vWF Activity Change in Ovarian Cancer Patients [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/dynamics-of-adamts13-and-vwf-activity-change-in-ovarian-cancer-patients/. Accessed September 27, 2023.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/dynamics-of-adamts13-and-vwf-activity-change-in-ovarian-cancer-patients/